• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    iBio Reports Fiscal Third Quarter 2025 Financial Results

    5/2/25 8:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IBIO alert in real time by email

    SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.

    "During the third quarter we were able to broaden our access to investors given our move to Nasdaq and subsequently in April, strengthened our financial position with a $6.2 million warrant-inducement equity raise, positioning us for continued growth and keeping us on track for regulatory submission of IBIO-600 in 2026," said Martin Brenner, Ph.D., DVM, iBio's Chief Executive Officer and Chief Scientific Officer. "At the same time, we made significant strides in our pipeline, with promising non-human primate data for IBIO-600 and the in-licensing of a first-in-class Activin E antibody, two antibodies we truly believe are bringing us closer to fulfilling our mission of delivering transformative therapies to patients suffering from cardiometabolic diseases and obesity."

    Fiscal Third Quarter 2025 & Recent Corporate Updates:

    • Began trading on the Nasdaq Stock Exchange under the ticker symbol "IBIO," marking a significant corporate milestone that enhances visibility, improves trading liquidity, and aligns with the company's strategy to attract long-term institutional investors.
    • Reported non-human primate data for IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, demonstrating extended half-life and dose dependent muscle growth. Simultaneously, iBio announced interim in vivo results for a first-in-class Activin E antibody showing fat-selective weight loss alone and in combination with semaglutide.
    • In-licensed the aforementioned first-in-class Activin E-targeting antibody from AstralBio, expanding iBio's cardiometabolic and obesity pipeline.
    • Raised $6.2 million in gross proceeds through a warrant inducement transaction with institutional investors, strengthening our balance sheet and providing additional working capital to support advancements in our pipeline.

    Fiscal Third Quarter 2025 Financial Results:

    • R&D expenses for the three months ending March 31, 2025 and 2024 were $1.9 million and $0.9 million, respectively, an increase of approximately $1.0 million. The growth in R&D expenses is mainly due to increased spending on consultants and outside services, consumable supplies, and personnel-related costs as a result of advancing research activities to support our IBIO-600 and Activin E programs.
    • G&A expenses for the three months ending March 31, 2025 and 2024 were approximately $3.0 million and $2.7 million, respectively, an increase of $0.3 million. The increase is primarily attributable to growth in IT related costs, consulting fees and franchise taxes, partially offset by lower professional service fees.
    • Net loss from continuing operations for the three months ending March 31, 2025 was approximately $4.9 million, or $0.49 per share, compared to a net loss from continuing operations of approximately $2.6 million, or $0.71 per share, in the same period of fiscal 2024.
    • Cash, cash equivalents and restricted cash as of March 31, 2025, was approximately $5.2 million, inclusive of $0.2 million of restricted cash.   Subsequent to the warrant inducement transaction in April, cash, cash equivalents and restricted cash was approximately $10.5 million as of May 1, 2025.

    About iBio, Inc.

    iBio (Nadaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.  For more information, visit www.ibioinc.com or follow us on LinkedIn.

    Safe Harbor Statement

    Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding the events of the quarter ended March 31, 2025 and April 2025 positioning the Company for continued growth; the Company's progress toward a regulatory submission of IBIO-600 in 2026; the promise of the non-human primate data for IBIO-600; IBIO-600 and Activin E antibody bringing the Company closer to delivering transformative therapies; the Company's listing on Nasdaq enhancing visibility, improving trading liquidity, and attracting long-term institutional investors; IBIO-600's potential to be a best-in-class long-acting anti-myostatin antibody; and the proceeds of the warrant inducement transaction being used to support advancements to the Company's pipeline. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including iBio's ability to submit a regulatory submission of iBIo-600 in 2026; to successfully develop iBIO-600 and Activin E antibody; attract long term institutional investors; -leverage its AI-driven platform to transform the treatment landscape for patients with cardiometabolic diseases and obesity with more effective, targeted therapies addressing the underlying causes of these conditions while improving overall metabolic health and quality of life; extend the half-life of IBIO-600; advance as a clinical-stage biotech; create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; and transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine the ability to advance iBio's internal pipeline priorities in immuno-oncology and cardiometabolics, and drive partnerships in new therapeutic areas, the ability to finance when needed and the risk factors described in the Company's Annual Report on Form 10-K for the year ended June 30, 2024, and the Company's subsequent filings with the SEC, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iBio, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

    Corporate Contact:

    iBio, Inc.

    Investor Relations

    [email protected]

    Media Contacts:

    Ignacio Guerrero-Ros, Ph.D., or David Schull

    Russo Partners, LLC

    [email protected]

    [email protected]

    (858) 717-2310 or (646) 942-5604



    Primary Logo

    Get the next $IBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IBIO

    DatePrice TargetRatingAnalyst
    5/28/2024$5.00Buy
    Chardan Capital Markets
    11/29/2021$1.50Mkt Outperform
    JMP Securities
    11/29/2021$1.50Outperform
    JMP Securities
    More analyst ratings

    $IBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by iBio Inc.

      SC 13G - iBio, Inc. (0001420720) (Subject)

      11/14/24 8:47:49 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by iBio Inc.

      SC 13G/A - iBio, Inc. (0001420720) (Subject)

      11/14/24 4:48:52 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by iBio Inc. (Amendment)

      SC 13G/A - iBio, Inc. (0001420720) (Subject)

      4/9/24 5:22:43 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on iBio with a new price target

      Chardan Capital Markets initiated coverage of iBio with a rating of Buy and set a new price target of $5.00

      5/28/24 7:42:07 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on iBio with a new price target

      JMP Securities initiated coverage of iBio with a rating of Mkt Outperform and set a new price target of $1.50

      11/29/21 7:34:24 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on iBio with a new price target

      JMP Securities initiated coverage of iBio with a rating of Outperform and set a new price target of $1.50

      11/29/21 7:32:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Duran Felipe bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 472% to 11,139 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:34:37 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Brenner Martin bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 101% to 18,316 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:34:02 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Banjak Marc bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 490% to 11,066 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:33:31 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

      Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscleStrong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its first-in-class Activin E antibody unveiled in Janu

      5/5/25 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Fiscal Third Quarter 2025 Financial Results

      SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress. "During the third quarter we were able to broaden our access to investors given our move to Nasdaq and subsequently in April, strengthened our financial position with a $6.2 million warrant-inducement equity raise, positioning us for continued growth and keeping us on track for regulatory submission of IBIO-600 in 2026," said Martin Brenner, Ph.D., DVM, iBio's Chief Executive Officer and Chief Scientific Officer. "At the same time, we made significant strides in our pipeline, with promising non

      5/2/25 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Raises $6.2 Million Through Warrant Inducement Transaction

      SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the "Existing Warrants"), wherein the investors agreed to exercise the Existing Warrants to purchase 5,626,685 shares of common stock at a reduced exercise price of $1.11 per share, resulting in gross proceeds of approximately $6.2 million, before deducting advisory fees and certain other expenses. The Company intends to use the net proceeds for worki

      4/29/25 1:43:30 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Banjak Marc

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:01:30 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Duran Felipe

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:00:59 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Brenner Martin

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:00:12 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Financials

    Live finance-specific insights

    See more
    • iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

      – Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company") announces today that it has entered into a collaboration agreement with AstralBio,

      3/27/24 7:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

      BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces preliminary unaudited financial results for the fiscal year ended June 30, 2022, and provides a corporate update. "We have continued to take important steps toward achieving our strategic objective of becoming a leading biotechnology company with a focus on developing innovative immunotherapies," said Tom Isett, Chairman & CEO of iBio. "Chief among these was the RubrYc asset acquisition, which provides us with a differentiated, AI-powered drug di

      9/27/22 4:10:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline

      – Positions Company for leadership in AI-powered drug discovery – – Expands iBio's immuno-oncology pipeline with three new candidates – – Hosting investor call on September 27th to discuss transaction, the Company's transformation and FY2022 financial results – SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announced that it closed on the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, Inc. ("RubrYc") after it entered into a definitive asset purchase agreement (the

      9/21/22 8:30:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • iBio to Begin Trading on the Nasdaq Stock Exchange

      SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol "IBIO." The Company's common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025. Martin Brenner, Ph.D., DVM, iBio's CEO and Chief Scientific Officer, commented, "We are pleased to announce our listing on the Nas

      2/19/25 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Strengthens Board with Appointment of Two New Independent Directors

      SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and António Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. "These appointments expand and strengthen our board to align with iBio's vision of becoming a next-generation antibody discovery and development company with a robust clinical pipeline of therapeutic antibodies for cardiometabolic diseases and oncology. As a seasoned CFO, David brings extensive financial experience and industry relationships that will benefit iBio as we

      11/25/24 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Fiscal First Quarter 2025 Financial Results

      SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. "In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progressing early work on additional targets. We strengthened our leadership team by hiring a seasoned business development executive, Kristi Sarno—a move essential to our efforts to critically enable new partners in antibody development for challenging targets," said CEO and

      11/12/24 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    SEC Filings

    See more
    • SEC Form D filed by iBio Inc.

      D - iBio, Inc. (0001420720) (Filer)

      5/7/25 9:50:45 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by iBio Inc.

      10-Q - iBio, Inc. (0001420720) (Filer)

      5/2/25 8:29:28 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - iBio, Inc. (0001420720) (Filer)

      5/2/25 8:05:54 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care